Centessa Pharmaceuticals (NASDAQ:CNTA) PT Raised to $35.00

Centessa Pharmaceuticals (NASDAQ:CNTA) had its target price upped by BMO Capital Markets from $20.00 to $35.00 in a research report sent to investors on Monday, Benzinga reports. They currently have an outperform rating on the stock.

A number of other research analysts also recently commented on the company. Guggenheim upped their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a buy rating in a research note on Wednesday, September 11th. Jefferies Financial Group increased their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a buy rating in a report on Wednesday, September 11th. Oppenheimer reissued an outperform rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Finally, Morgan Stanley raised their price target on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the company an equal weight rating in a research note on Friday, June 21st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of Buy and a consensus price target of $25.17.

Centessa Pharmaceuticals Trading Up 0.9 %

NASDAQ CNTA opened at $15.85 on Monday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29. Centessa Pharmaceuticals has a one year low of $5.15 and a one year high of $17.59. The company has a 50-day simple moving average of $12.15 and a 200-day simple moving average of $10.60. The firm has a market capitalization of $1.59 billion, a PE ratio of -11.16 and a beta of 1.44.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). On average, equities analysts forecast that Centessa Pharmaceuticals will post -1.61 earnings per share for the current year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 12,198 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total transaction of $148,449.66. Following the transaction, the insider now owns 241,171 shares in the company, valued at $2,935,051.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total transaction of $148,449.66. Following the completion of the transaction, the insider now directly owns 241,171 shares of the company’s stock, valued at approximately $2,935,051.07. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Saurabh Saha sold 175,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total value of $2,891,000.00. Following the completion of the sale, the chief executive officer now directly owns 776,924 shares in the company, valued at approximately $12,834,784.48. The disclosure for this sale can be found here. In the last three months, insiders sold 216,873 shares of company stock valued at $3,472,000. Company insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several large investors have recently made changes to their positions in the business. First Light Asset Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter worth approximately $33,923,000. Farallon Capital Management LLC increased its holdings in shares of Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after buying an additional 1,625,000 shares in the last quarter. Octagon Capital Advisors LP lifted its position in shares of Centessa Pharmaceuticals by 333.2% during the 4th quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock valued at $16,398,000 after acquiring an additional 1,584,500 shares during the last quarter. Driehaus Capital Management LLC boosted its stake in shares of Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after acquiring an additional 987,997 shares in the last quarter. Finally, Perceptive Advisors LLC grew its holdings in shares of Centessa Pharmaceuticals by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock worth $35,518,000 after acquiring an additional 850,000 shares during the last quarter. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.